Sandoz Targets Double Sales by 2035
Swiss drugmaker Sandoz plans to more than double annual net sales by 2035 through a major expansion of its biosimilars portfolio. The company targets mid-single-digit sales growth and plans to increase its biosimilar drugs significantly.
Xurve View
Insights:
Xurve View